Mutational profiling of low‐grade gliomas identifies prognosis and immunotherapy‐related biomarkers and tumour immune microenvironment characteristics
Open Access
- 1 October 2021
- journal article
- research article
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 25 (21) , 10111-10125
Abstract
Low‐grade glioma (LGG) is a heterogeneous tumour with the median survival rate less than 10 years. Therefore, it is urgent to develop efficient immunotherapy strategies of LGG. In this study, we analysed mutation profiles based on the data of 510 LGG patients from the Cancer Genome Atlas (TCGA) database and investigated the prognostic value of mutated genes and evaluate their immune infiltration. Tumor Immune Dysfunction and Exclusion (TIDE) algorithm was used to indicate the characteristics of gliomas that respond to immune checkpoint blockade (ICB) therapy. Univariate and multivariate cox regression analysis was performed to identify indicators to construct the nomogram model. 485 (95.47%) of 508 LGG samples showed gene mutation, and 9 mutated genes were significantly related to overall survival (OS), among which 6 mutated genes were significantly correlated with OS between mutation and wildtypes. Immune infiltration and immune score analyses revealed that these six mutated genes were significantly associated with tumour immune microenvironment in LGG. The response of LGG with different characteristics to ICB was evaluated by TIDE algorithm. Finally, CIC gene was screened through both univariate and multivariate Cox regression analyses, and the nomogram model was established to determine the potential prognostic value of CIC in LGG. Our study provides comprehensive analysis of mutated genes in LGG, supporting modulation of mutated genes in the management of LGG.Keywords
Funding Information
- National Natural Science Foundation of China (81171138, 81471279)
This publication has 45 references indexed in Scilit:
- Oligodendroglioma: pathology, molecular mechanisms and markersActa Neuropathologica, 2015
- New Developments in the Pathogenesis and Therapeutic Targeting of the IDH1 Mutation in GliomaInternational Journal of Medical Sciences, 2015
- IDH1/IDH2but NotTP53Mutations Predict Prognosis in Bulgarian Glioblastoma PatientsBioMed Research International, 2014
- IDH1 and IDH2 Mutations in GliomasCurrent Neurology and Neuroscience Reports, 2013
- clusterProfiler: an R Package for Comparing Biological Themes Among Gene ClustersOMICS: A Journal of Integrative Biology, 2012
- Seizure characteristics and outcomes in 508 Chinese adult patients undergoing primary resection of low-grade gliomas: a clinicopathological studyNeuro-Oncology, 2011
- Tumor Immune EvasionScience, 2010
- IDH1 Gene Mutations: A New Paradigm in Glioma Prognosis and Therapy?The Oncologist, 2010
- Phase II Study of Protracted Daily Temozolomide for Low-Grade Gliomas in AdultsClinical Cancer Research, 2008
- Low-Grade Gliomas in AdultsThe Oncologist, 2006